World Macular Edema and Macular Degeneration Market - Opportunities and Forecasts, 2019-2026
|
LI_18620
|
Pages: NA
|
Jan 2020 |
1354 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
Macular edema is a condition in which the retinal layers around the fovea is accumulated by the fluid that leads to the vision impairment and also might lead to the vision loss. Macular edema can be of two types, namely cystoid macular edema and diabetic macular edema. In addition to this, the macular degeneration is a condition in which the loss of vision occurs due to the retinal damage and it majorly affects adults (>50 years). Macular degeneration is a painless disease condition that leads to the loss of central vision. Macular degeneration is of two types, namely wet macular degeneration and dry macular degeneration. Growing aging population has increasingly become an issue that leads to the growing number of macular edema and degeneration case, contributing to the growth of the market. The therapies such as anti-vascular endothelial growth factor drugs for the treatment of diabetic macular edema and Lucentis (ranibizymab) & Avastin drugs for the macular degeneration have played a significant role in the growth of global macular edema and degeneration market.
Global macular edema and macular degeneration market is segmented based on the types of macular edema and macular degeneration. In addition to this, the Macular edema market is segmented based on its type, namely cystoid macular edema (CME) and diabetic macular edema (DME). Macular degeneration market is segmented based on its types such as dry age-related macular degeneration (Dry AMD) and wet age ‐related macular degeneration (wet AMD). The global macular edema and degeneration market is classified based on the treatment into macular edema diagnosis and macular degeneration diagnosis. Based on geography, the market is segmented into North America, Europe, Asia-pacific and LAMEA.
Companies such as Novartis, Roche, Bayer, Allergan, Ampio Pharmaceuticals and valeant Pharmaceuticals International are the leading players operating in the market. Leading players such as Bayer and Novartis are focusing on the joint venture strategy to develop new treatment option for the macular edema and macular degeneration.
KEY BENEFITS
- Market analysis based on the current market scenario and expected future trends to enable stakeholders take strategic decision
- Market estimation for techniques and geographic segment is derived from current market scenario and expected market trends
- Market attractiveness analysis has been included for the treatment types and geographic regions with detailed analysis of factors responsible for rapid growth of the market segments
- The report provides analysis of key drivers, restrains and opportunities of macular edema and degeneration market including its impact on the global market
- Value chain analysis, Porter’s five force model, top investment pockets (GE9 Cell Matrix) are analyzed and presented in detail in the report so that the decision makers can receive clear picture of macular edema and degeneration market
- The projections in the report are made by analyzing the current market trends and future market potential for the period of 2014‐2021 in terms of value
Market Segmentation
Macular edema and degeneration market is segmented based on its types, treatment and geography.
MARKET BY TYPE
- Macular Edema
- Cystoid macular edema (CME)
- Diabetic macular edema (DME)
- Macular Degeneration
- Dry age-related macular degeneration
- Wet age-related macular degeneration
MARKET BY TREATMENT
- Drug therapy
- Laser treatment
- Implantable telescope
MARKET BY GEOGRAPHY
- North America
- Europe
- Asia-Pacific
- LAMEA
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/ TOP PLAYER POSITIONING, 2017
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CYSTOID MACULAR EDEMA
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. DIABETIC MACULAR EDEMA
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. DRY AGE-RELATED MACULAR DEGENERATION
4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. WET AGE-RELATED MACULAR DEGENERATION
4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY TREATMENT
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. DRUG THERAPY
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. LASER TREATMENT
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. OTHERS
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. AMBULATORY SURGICAL CENTERS & CLINICS
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends, growth factors & opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S. macular edema & macular degeneration market size and forecast
7.2.2.1.1. U.S. macular edema & macular degeneration market, by type
7.2.2.1.2. U.S. macular edema & macular degeneration market, by treatment
7.2.2.1.3. U.S. macular edema & macular degeneration market, by end user
7.2.2.2. Canada macular edema & macular degeneration market size and forecast
7.2.2.2.1. Canada macular edema & macular degeneration market, by type
7.2.2.2.2. Canada macular edema & macular degeneration market, by treatment
7.2.2.2.3. Canada macular edema & macular degeneration market, by end user
7.2.2.3. Mexico macular edema & macular degeneration market size and forecast
7.2.2.3.1. Mexico macular edema & macular degeneration market, by type
7.2.2.3.2. Mexico macular edema & macular degeneration market, by treatment
7.2.2.3.3. Mexico macular edema & macular degeneration market, by end user
7.2.3. North America macular edema & macular degeneration market, by type
7.2.4. North America macular edema & macular degeneration market, by treatment
7.2.5. North America macular edema & macular degeneration market, by end user
7.3. EUROPE
7.3.1. Key market trends, growth factors & opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany macular edema & macular degeneration market size and forecast
7.3.2.1.1. Germany macular edema & macular degeneration market, by type
7.3.2.1.2. Germany macular edema & macular degeneration market, by treatment
7.3.2.1.3. Germany macular edema & macular degeneration market, by end user
7.3.2.2. France macular edema & macular degeneration market size and forecast
7.3.2.2.1. France macular edema & macular degeneration market, by type
7.3.2.2.2. France macular edema & macular degeneration market, by treatment
7.3.2.2.3. France macular edema & macular degeneration market, by end user
7.3.2.3. UK macular edema & macular degeneration market size and forecast
7.3.2.3.1. UK macular edema & macular degeneration market, by type
7.3.2.3.2. UK macular edema & macular degeneration market, by treatment
7.3.2.3.3. UK macular edema & macular degeneration market, by end user
7.3.2.4. Italy macular edema & macular degeneration market size and forecast
7.3.2.4.1. Italy macular edema & macular degeneration market, by type
7.3.2.4.2. Italy macular edema & macular degeneration market, by treatment
7.3.2.4.3. Italy macular edema & macular degeneration market, by end user
7.3.2.5. Spain macular edema & macular degeneration market size and forecast
7.3.2.5.1. Spain macular edema & macular degeneration market, by type
7.3.2.5.2. Spain macular edema & macular degeneration market, by treatment
7.3.2.5.3. Spain macular edema & macular degeneration market, by end user
7.3.2.6. Rest of Europe macular edema & macular degeneration market size and forecast
7.3.2.6.1. Rest of Europe macular edema & macular degeneration market, by type
7.3.2.6.2. Rest of Europe macular edema & macular degeneration market, by treatment
7.3.2.6.3. Rest of Europe macular edema & macular degeneration market, by end user
7.3.3. Europe macular edema & macular degeneration market, by type
7.3.4. Europe macular edema & macular degeneration market, by treatment
7.3.5. Europe macular edema & macular degeneration market, by end user
7.4. ASIA-PACIFIC
7.4.1. Key market trends, growth factors & opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan macular edema & macular degeneration market size and forecast
7.4.2.1.1. Japan macular edema & macular degeneration market, by type
7.4.2.1.2. Japan macular edema & macular degeneration market, by treatment
7.4.2.1.3. Japan macular edema & macular degeneration market, by end user
7.4.2.2. China macular edema & macular degeneration market size and forecast
7.4.2.2.1. China macular edema & macular degeneration market, by type
7.4.2.2.2. China macular edema & macular degeneration market, by treatment
7.4.2.2.3. China macular edema & macular degeneration market, by end user
7.4.2.3. Australia macular edema & macular degeneration market size and forecast
7.4.2.3.1. Australia macular edema & macular degeneration market, by type
7.4.2.3.2. Australia macular edema & macular degeneration market, by treatment
7.4.2.3.3. Australia macular edema & macular degeneration market, by end user
7.4.2.4. India macular edema & macular degeneration market size and forecast
7.4.2.4.1. India macular edema & macular degeneration market, by type
7.4.2.4.2. India macular edema & macular degeneration market, by treatment
7.4.2.4.3. India macular edema & macular degeneration market, by end user
7.4.2.5. South Korea macular edema & macular degeneration market size and forecast
7.4.2.5.1. South Korea macular edema & macular degeneration market, by type
7.4.2.5.2. South Korea macular edema & macular degeneration market, by treatment
7.4.2.5.3. South Korea macular edema & macular degeneration market, by end user
7.4.2.6. Rest of Asia-Pacific macular edema & macular degeneration market size and forecast
7.4.2.6.1. Rest of Asia-Pacific macular edema & macular degeneration market, by type
7.4.2.6.2. Rest of Asia-Pacific macular edema & macular degeneration market, by treatment
7.4.2.6.3. Rest of Asia-Pacific macular edema & macular degeneration market, by end user
7.4.3. Asia-Pacific macular edema & macular degeneration market, by type
7.4.4. Asia-Pacific macular edema & macular degeneration market, by treatment
7.4.5. Asia-Pacific macular edema & macular degeneration market, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors & opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil macular edema & macular degeneration market size and forecast
7.5.2.1.1. Brazil macular edema & macular degeneration market, by type
7.5.2.1.2. Brazil macular edema & macular degeneration market, by treatment
7.5.2.1.3. Brazil macular edema & macular degeneration market, by end user
7.5.2.2. Saudi Arabia macular edema & macular degeneration market size and forecast
7.5.2.2.1. Saudi Arabia macular edema & macular degeneration market, by type
7.5.2.2.2. Saudi Arabia macular edema & macular degeneration market, by treatment
7.5.2.2.3. Saudi Arabia macular edema & macular degeneration market, by end user
7.5.2.3. South Africa macular edema & macular degeneration market size and forecast
7.5.2.3.1. South Africa macular edema & macular degeneration market, by type
7.5.2.3.2. South Africa macular edema & macular degeneration market, by treatment
7.5.2.3.3. South Africa macular edema & macular degeneration market, by end user
7.5.2.4. Rest of LAMEA. macular edema & macular degeneration market size and forecast
7.5.2.4.1. Rest of LAMEA macular edema & macular degeneration market, by type
7.5.2.4.2. Rest of LAMEA macular edema & macular degeneration market, by treatment
7.5.2.4.3. Rest of LAMEA macular edema & macular degeneration market, by end user
7.5.3. LAMEA macular edema & macular degeneration market, by type
7.5.4. LAMEA macular edema & macular degeneration market, by treatment
7.5.5. LAMEA macular edema & macular degeneration market, by end user
CHAPTER 8 COMPANY PROFILES
8.1. AMPIO PHARMACEUTICALS
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. ALIMERA SCIENCES
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. NOVARTIS INTERNATIONAL AG
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. REGENERON PHARMACEUTICALS, INC.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. F. HOFFMANN LA ROCHE AG
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. BAYER AG
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. OHR PHARMACEUTICAL, INC.
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. SANTEN PHARMACEUTICAL CO., LTD.
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. OPHTHOTECH CORPORATION
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
World Macular Edema and Macular Degeneration Market- Opportunities and Forecasts, 2019-2026
- Online Only
-
$3,456$3,041 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,379 - Restricted to one authorized user
- One print only
- Available in Excel
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,370$4,726 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,676 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$7,916 - Unlimited within company/enterprise
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Access
- $0.00
- Published Content E-Access
- Company Profiles E-Access
- Newly Added Content Access
- 10 PDF Downloads
- 5 Excel Data Pack Downloads
- 250 Company Profiles PDF Downloads
-
Start reading
Buy Now
,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.